logo
After Falling on Earnings, Should You Buy the Dip in ASML Stock?

After Falling on Earnings, Should You Buy the Dip in ASML Stock?

Yahoo23-07-2025
Key Points
ASML has struggled over the past year due to export restrictions on China and order delays.
The stock tumbled again after management said it wasn't sure revenue would grow in 2026.
Despite those troubles, the stock should still pay off for patient investors in the long run.
10 stocks we like better than ASML ›
On the surface, ASML Holding's (NASDAQ: ASML) competitive advantages are clear. It's the world's only maker of extreme ultraviolet lithography (EUV) machines, which companies like Taiwan Semiconductor Manufacturing rely on to make the world's most advanced chips.
Typically, being the only producer of a high-tech machine is an advantageous position for a company, and it is for ASML, but it hasn't been enough to make the stock a winner recently. While the rest of the artificial intelligence (AI) and semiconductor sectors have been soaring, ASML is down sharply from its peak last year. After delivering an underwhelming earnings report on Wednesday, the stock fell again, losing 8.3%, and it's now off 32% from that record last year.
Because its business involves selling very expensive machines, which can cost around $200 million, ASML's results can be volatile quarter to quarter. In the second quarter, the company reported revenue growth of 23% to 7.69 billion euros. This beat estimates at 7.52 billion euros, though that was down less than 1% in the quarter.
The company sold 67 new lithography machines, down from 73 in the first quarter. Net bookings were better than expected, increasing from 3.9 billion euros in Q1 to 5.5 billion, a positive growth signal. 2.3 billion euros' worth of those orders were for EUV machines.
Further down the income statement, profit was also down slightly on a sequential basis. Gross margin fell from 54% to 53.7%, and earnings per share declined from 6.00 euros in Q1 to 5.90.
What's ailing ASML
While the second-quarter results were in line with estimates, there were some challenges that are outside of the company's control, but continue to plague the business.
First, restrictions on exporting semiconductor technology to China have posed a problem for ASML. Management said on the earnings call that it was lowering its backlog by 1.4 billion euros to 33 billion euros due to order cancellations related to those restrictions. That reduction was related to deep ultraviolet (DUV) lithography machines, which are less advanced than the EUV machines it's best known for.
What seemed to be more disappointing to investors were its cautious comments about 2026. CEO Roger Dassen said: "Looking at 2026, we see that our AI customers' fundamentals remain strong. At the same time, we continue to see increasing uncertainty driven by macroeconomic and geopolitical developments. Therefore, while we still prepare for growth in 2026, we cannot confirm it at this stage."
Essentially, management is unsure that revenue will grow next year. For the third quarter, the company said it expects 15% revenue growth, to 7.4 billion euros to 7.9 billion euros.
What it means for ASML
ASML isn't the first tech stock to get dumped by investors for a lack of clarity with its guidance. A number of companies have chosen not to offer guidance due to uncertainty around tariffs, export controls, and volatility in the broader global economy.
Arm Holdings did not offer full-year guidance for its new fiscal year in its earnings report in May, and the stock fell as a result. However, that decision wasn't a reflection of weakness, but of uncertainty in both the macroeconomy and with its customer base, which also had not given guidance.
However, the strength in AI-related demand is a positive sign for ASML, and investors shouldn't lose sight of long-term tailwinds from AI. For now, ASML is struggling with the vicissitudes of the semiconductor equipment cycle, which operates on a different course than the broader chip sector, but equipment upgrades will come eventually.
After Wednesday's sell-off, the stock now trades at a price-to-earnings ratio of about 30, which seems like a fair price to pay for an industry leader with a monopoly in new technology and the potential for accelerating growth from AI. The company continues to expect 44 billion to 60 billion euros in revenue by 2030, and gross margin improving to 56% to 60%.
That implies double-digit revenue growth and expanding margins. If the company can deliver on that, the stock should be a winner over the next five years.
Do the experts think ASML is a buy right now?
The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did ASML make the list?
When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,048% vs. just 180% for the S&P — that is beating the market by 867.59%!*
Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!*
The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 21, 2025
Jeremy Bowman has positions in ASML, Arm Holdings, and Taiwan Semiconductor Manufacturing. The Motley Fool has positions in and recommends ASML and Taiwan Semiconductor Manufacturing. The Motley Fool has a disclosure policy.
After Falling on Earnings, Should You Buy the Dip in ASML Stock? was originally published by The Motley Fool
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why Nektar Therapeutics Stock Popped 6% on Friday
Why Nektar Therapeutics Stock Popped 6% on Friday

Yahoo

timean hour ago

  • Yahoo

Why Nektar Therapeutics Stock Popped 6% on Friday

Key Points Investors were reacting to the biotech's second-quarter earnings report. Revenue was higher than analysts expected, although the net loss was deeper than the consensus. 10 stocks we like better than Nektar Therapeutics › Biotech Nektar Therapeutics (NASDAQ: NKTR) unveiled its latest quarterly earnings after the stock market's close on Thursday, and the investor reaction was strong the following day. Happily for Nektar, it was largely positive, and the share price increased by 6% today. This was well higher than the 0.8% gain posted by the S&P 500 index. Sweet results In its second quarter, Nektar booked total revenue of just under $11.2 million, which was less than half of the nearly $23.5 million in the same period of 2024. All of this derived from noncash royalty revenue connected to the sales of future royalties. This isn't unusual for a biotech without a commercialized product that depends on royalties and other payouts from partners. Nektar added that its cash and investments in marketable securities stood at just under $176 million at the end of the quarter (June 30). That, plus the roughly $107.5 million it should reap from a recent secondary share issue, should fund its operations into the first quarter of 2027. Meanwhile, the company's net loss for the second quarter was slightly over $39 million, or $2.78 per share. On average, analysts were projecting Nektar would book $9.7 million in revenue and a net loss of only $0.20 per share. I should note here that it can be challenging for even the most experienced professionals to estimate the results of biotechs that don't draw meaningful revenue from commercialized products. On a fast track All that said, there are several potential tailwinds for Nektar just now, and the company wasn't shy about itemizing them in its earnings release. Among the more promising is the U.S. Food and Drug Administration granting its Fast Track designation for rezpegaldesleukin, Nektar's investigational drug targeting severe-to-very-severe alopecia areata (a skin disorder). Do the experts think Nektar Therapeutics is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Nektar Therapeutics make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,047% vs. just 181% for the S&P — that is beating the market by 865.68%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Nektar Therapeutics Stock Popped 6% on Friday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Craig-Hallum Maintains Buy on Enphase (ENPH) Despite Clean Energy Headwinds
Craig-Hallum Maintains Buy on Enphase (ENPH) Despite Clean Energy Headwinds

Yahoo

time2 hours ago

  • Yahoo

Craig-Hallum Maintains Buy on Enphase (ENPH) Despite Clean Energy Headwinds

Enphase Energy, Inc. (NASDAQ:ENPH) is one of the best battery tech stocks to buy right now. Eric Stine, an analyst at Craig-Hallum, has kept a Buy rating on Enphase Energy, Inc. (NASDAQ:ENPH), without a price target. Stine showed continued support for the company despite ongoing challenges in the clean energy sector. While the solar industry has seen slower demand recently, some analysts still see room for growth in firms with strong technology and stable operations. A solar panel array stretched across a large open field, its glimmering panels reflecting the sun. Enphase Energy makes microinverters and energy management systems. These are used mainly in solar power setups, helping improve how energy is stored and used. The company has faced recent pressures, like weaker sales and cautious consumer spending, but it still holds a solid position in its field. Analysts believe that demand will return or that the company will adjust its costs and production to better fit market conditions. Though the stock has dropped since the end of 2022, some believe the lower price offers a chance for recovery. The analyst's decision to maintain a positive view could suggest belief in the company's ability to perform better in the future as the energy market changes. While we acknowledge the potential of ENPH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 12 Best Performing AI Stocks So Far in 2025 and 10 Best Military Tech Stocks to Buy Now Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Benchmark Hikes Enovix (ENVX) Price Target, Citing AI-1 Platform Strength
Benchmark Hikes Enovix (ENVX) Price Target, Citing AI-1 Platform Strength

Yahoo

time2 hours ago

  • Yahoo

Benchmark Hikes Enovix (ENVX) Price Target, Citing AI-1 Platform Strength

Enovix Corporation (NASDAQ:ENVX) is one of the best battery tech stocks to buy right now. Benchmark has raised its price target on Enovix Corporation (NASDAQ:ENVX) from $15 to $25 on July 25. The firm also kept its Buy rating on the stock. The decision to raise the target is based on how well Enovix has been performing lately. The analyst pointed to the company's recent progress and said it shows strong execution. A technician in a hardhat examining a subsea battery system. Another reason for the higher price target is the AI-1 platform. According to the analyst, this platform is very important for Enovix's future. It is seen as a big step forward for the company. The AI-1 platform could help Enovix grow and stay competitive in the battery technology space. Because of this, the analyst believes the company has more value than before. Enovix has been working hard on new battery technology. The AI-1 platform shows that the company is serious about leading in this space. Benchmark seems confident that Enovix is moving in the right direction. With better execution and promising new products, the stock could continue to go up. In summary, the raised price target reflects stronger performance and the growing importance of the company's new technology. Benchmark remains positive about Enovix's future and continues to recommend buying the stock. Enovix is a battery technology company developing advanced lithium-ion batteries with silicon-anode architecture. Its innovative designs aim to deliver higher energy density, improved safety, and better performance for applications in consumer electronics, wearables, and future electric vehicles. While we acknowledge the potential of ENVX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 12 Best Performing AI Stocks So Far in 2025 and 10 Best Military Tech Stocks to Buy Now Disclosure: None.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store